JANUARY 14, 2025
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101 Biophytis announces that it has entered exclusive negotiations with a leading Chinese pharmaceutical
JANUARY 8, 2025
Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program Cash contribution of €2.5 million from existing and
JANUARY 6, 2025
Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction Biophytis announces today that the